News Center

News Center

Complementary advantages: World's first SGLT-2/DPP-4 dual-target inhibitor approved for clinical trials

Recently, CGT-2201, a Class 1 innovative drug developed by Shengshi Taikang and targeting both SGLT-2 and DPP-4, has received implicit approval from the National Medical Products Administration for clinical trials. As a dual-target inhibitor, CGT-2201 addresses two key metabolic pathways closely linked to diabetes, making it particularly effective in treating diabetes and its related complications, such as diabetic nephropathy and non-alcoholic fatty liver disease. China currently boasts the largest diabetic population globally, with 141 million people diagnosed as of 2021. Among these patients, an estimated 20–40% may develop diabetic kidney disease—a serious complication that significantly impacts quality of life and increases healthcare costs. While sodium-glucose co-transporter 2 (SGLT-2) inhibitors have demonstrated robust renal protective effects in clinical settings, their use is often limited by inherent risks of reproductive and urinary system infections. To address this gap, Shengshi Taikang has leveraged its proprietary small-molecule chimera drug technology platform to design and develop CGT-2201, a novel compound that combines the benefits of SGLT-2 inhibition with the favorable properties of DPP-4 inhibition. By simultaneously reducing glucose reabsorption in the kidneys via SGLT-2 blockade and preserving GLP-1 levels through DPP-4 inhibition, CGT-2201 achieves a synergistic dual-action mechanism, enhancing blood sugar control while minimizing urinary and genital tract infection risks—key side effects associated with existing SGLT-2 inhibitors. Importantly, because CGT-2201 does not rely on renal excretion, it imposes no restrictions on patients with impaired kidney function, offering a safer treatment option for those who might otherwise be excluded from current therapies. Building on this strong market demand and the unique characteristics of its target pathways, Shengshi Taikang has positioned CGT-2201 as a flagship product within its pipeline. The company’s cutting-edge chimera drug technology enables the creation of multi-functional, multi-targeted compounds with complementary mechanisms of action. CGT-2201 exemplifies this approach: it integrates the distinct advantages of both SGLT-2 and DPP-4 inhibition, effectively lowering glucose reabsorption in the kidneys while preserving GLP-1 activity to support insulin secretion. Clinical trial data indicate that even low doses of CGT-2201 achieve significant glycemic control, while higher doses further enhance safety profiles. Notably, the drug’s impressive efficacy-to-dose ratio suggests it could become a leading choice among SGLT-2 inhibitors, potentially setting a new standard in diabetes management. Founded in 2010 in Suzhou Industrial Park, Shengshi Taikang has assembled a seasoned leadership team with decades of global expertise spanning the entire pharmaceutical lifecycle. The company is dedicated to advancing high-quality, differentiated small-molecule drug innovation and commercialization. Leveraging an integrated drug R&D platform and a forward-thinking business strategy, Shengshi Taikang has cultivated a diverse pipeline covering multiple therapeutic areas, including diabetes, cancer, and autoimmune diseases. In the diabetes space, the company’s lead candidate, shenglitinib, has already been submitted to the NMPA for New Drug Application (NDA) and is currently under review. Phase 3 clinical trials have shown that even low doses can meet primary efficacy endpoints, while higher doses consistently demonstrate excellent safety profiles. This remarkable "dose-sparing" effect positions shenglitinib as a potential best-in-class treatment for diabetes, offering both superior blood sugar control and enhanced renal protection—a critical advantage for patients managing both diabetes and kidney-related complications. With CGT-2201 now poised to enter clinical trials, Shengshi Taikang continues to expand its portfolio of innovative solutions aimed at addressing unmet medical needs across the diabetes landscape.

Time:2023-04-20 11:50

< 1...345...8 >